Table 1 Demographics and baseline clinical characteristics
Patients (n=55) | |
|---|---|
HLA-B27 positive (%) | 53 (96%) |
Gender (male/female) (%) | 45 (82%)/10 (18%) |
Age, years (IQR) | 40 (32–48) |
Disease duration (IQR) | 5.5 (2.0–10.0) |
Baseline NSAID use (%) | 47 (85%) |
Infliximab/etanercept/adalimumab | 37 (67%)/12 (22%)/6 (11%) |
ASDAS | 3.9 (3.0–4.5) |
BASDAI (0–100) | 55.0 (44.0–72.8) |
Swollen joint count (0–28) | 0 (0-8) |
Serum CRP (mg/L) | 27.6 (1.2–162.0) |
Patients with a SpA feature, n (%) | 24 (44%) patients with 1 SpA feature 4 (7%) patients with 2 SpA features 2 (4%) patients with 3 SpA features |
Peripheral arthritis (%) | 12 (22%) |
Psoriasis (%) | 12 (22%) |
History of anterior uveitis (%) | 11 (20%) |
History of inflammatory bowel disease (%) | 3 (5%) |